Photo from academic.microsoft.com
Clinical trials of sodium–glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 (GLP1) receptor agonists have shown beneficial effects of these agents on kidney outcomes in patients with type 2… Click to show full abstract
Clinical trials of sodium–glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 (GLP1) receptor agonists have shown beneficial effects of these agents on kidney outcomes in patients with type 2 diabetes mellitus. Two new cohort studies now demonstrate that these findings are generalizable to the broad range of patients seen in clinical practice.
Keywords:
sglt2 inhibitors;
clinical practice;
renal outcomes;
outcomes sglt2;
inhibitors glp1
Journal Title: Nature Reviews Nephrology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Nature Reviews Nephrology
Year Published: 2020
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!